Notes to the Consolidated Statements of Financial Position (Tables)

12 Months Ended

Dec. 31, 2025

Notes to the Consolidated Statements of Financial Position [Abstract]

Schedule of Property and Equipment

Property and equipment

		Property and equipment
Cost
At January 1, 2024			1,491,525
Additions			22,723
Exchange differences			25,822
At December 31, 2024			1,540,070
Additions			108,257
Disposals			(61,268	)
Exchange differences			(50,001	)
At December 31, 2025			1,537,058

Accumulated depreciation
At January 1, 2024			(1,201,948	)
Depreciation charge for the year			(56,077	)
Exchange differences			(25,765	)
At December 31, 2024			(1,283,790	)
Depreciation charge for the year			(61,207	)
Disposals			47,254
Exchange differences			50,001
At December 31, 2025			(1,247,741	)

Net book value
At December 31, 2024			256,280
At December 31, 2025			289,317

Schedule of Right-of-Use Assets

Right-of-use assets

		Buildings				Cars				Total
Cost						(in €)
At January 1, 2024			2,661,118				174,134				2,835,252
Additions			—				68,604				68,604
Exchange differences			20,101				—				20,101
At December 31, 2024			2,681,219				242,738				2,923,957
Additions			451,427				—				451,427
Exchange differences			(38,922	)			—				(38,922	)
At December 31, 2025			3,093,724				242,738				3,336,462

Accumulated depreciation
At January 1, 2024			(1,633,020	)			(130,566	)			(1,763,586	)
Depreciation charge for the year			(353,426	)			(33,427	)			(386,852	)
Exchange differences			(15,151	)			—				(15,151	)
At December 31, 2024			(2,001,597	)			(163,993	)			(2,165,590	)
Depreciation charge for the year			(308,827	)			(33,486	)			(342,313	)
Exchange differences			33,107				—				33,107
At December 31, 2025			(2,277,318	)			(197,478	)			(2,474,796	)

Net book value
At December 31, 2024			679,622				78,745				758,367
At December 31, 2025			816,407				45,260				861,667

Schedule of Intangible Assets

Intangible assets

		Purchased IT-software				Advances paid for software				Total
Cost						(in €)
At January 1, 2024			716,130				25,977				742,107
Additions			6,607				17,541				24,148
Exchange differences			439				—				439
At December 31, 2024			723,176				43,518				766,694
Additions			39,019				—				39,019
Disposals			—				(31,582	)			(31,582	)
Exchange differences			(850	)			—				(850	)
At December 31, 2025			761,345				11,936				773,281

Accumulated amortization
At January 1, 2024			(673,289	)			—				(673,289	)
Amortization charge for the year			(42,185	)			—				(42,185	)
Exchange differences			(439	)			—				(439	)
At December 31, 2024			(715,913	)			—				(715,913	)
Amortization charge for the year			(15,963	)			—				(15,963	)
Exchange differences			850				—				850
At December 31, 2025			(731,026	)			—				(731,026	)

Net book value
At December 31, 2024			7,263				43,518				50,781
At December 31, 2025			30,319				11,936				42,255

Schedule of Lease Liabilities

Set out below, are the carrying amounts and the movements of the Group’s lease liabilities:

Lease liabilities		2025				2024
		(in €)
As of January 1			805,086				1,120,048
Additions			451,427				68,604
Payments			(357,583	)			(388,114	)
Short-term liability for accrued interest expense			4,768				(409	)
Foreign exchange difference			(5,779	)			4,959
As of December 31			897,917				805,086

Schedule of Amounts Recognized in Profit or Loss

The following are the amounts recognized in profit or loss:

		2025				2024				2023
						(in €)
Depreciation expense of right-of-use assets (see Note E.2.)			342,313				386,853				377,925
Interest expense on lease liabilities			36,547				19,770				19,090
Rental expense from leases			11,055				10,429				6,261
Thereof short-term leases (included in administrative expenses)			3,960				4,168				—
Thereof leases of low-value assets (included in administrative expenses)			7,095				6,261				6,261
Total amounts recognized in profit or loss			389,915				417,052				403,276

Schedule of Inventory

Inventory

		2025				2024				2023
						(in €)
Raw material and supplies			—				82,087				423,560
Unfinished goods			—				6,758,952				10,614,159
Finished goods			—				56,627				330,087
Total			—				6,897,666				11,367,807

Schedule of Other Assets

Other assets

		December 31, 2025				December 31, 2024
		(in €)
Non-current other assets
Prepaid expenses			151,198				204,233
Total non-current other assets			151,198				204,233
Current other assets
Prepayments on research & development projects			2,222,380				4,628,878
Prepaid expenses			923,832				354,948
Others			114,826				119,576
Total current other assets			3,261,038				5,103,402
Other assets from research allowances
Current other assets from research allowances			2,487,763				5,081,772
Total other assets from research allowances			2,487,763				5,081,772
Total other assets			5,899,999				10,389,407

Schedule of Applicable Tax Rate and Current Income Taxes Recognized in Profit or Loss

The table below shows a reconciliation between the product of loss before tax multiplied by the Company's applicable tax rate and current income taxes recognized in profit or loss.

InflaRx Group		2025				2024				2023
		(in €)
Loss for the period (accounting profit before income tax)			(45,621,498	)			(46,059,185	)			(42,667,529	)
Tax rate			28.6	%			28.6	%			28.6	%
Tax benefits at tax rate			13,089,429				13,159,368				12,160,545
Temporary differences and tax losses for which no deferred tax asset was recognized			(13,797,393	)			(14,577,752	)			(12,127,977	)
Non-recognition of tax effect on share-based payments			—				—				(32,182	)
Non-deductible expenses for tax purposes			(54,846	)			(56,721	)			(46,907	)
Tax free income			762,810				1,475,105				—
Taxes prior years			(12,282	)			(5,217	)			—
Other differences due to tax rate			—				—				46,521
Income tax			(12,282	)			(5,217	)			—

Schedule of Financial Assets and Liabilities

Set out below is an overview of financial assets and liabilities, other than cash and short-term deposits included in cash equivalents, held by the Group as at December 31, 2025 and December 31, 2024:

		December 31, 2025				December 31, 2024
		(in €)
Financial assets at amortized cost
Non-current financial assets			237,373				3,092,290
Thereof marketable securities			—				2,854,405
Current financial assets			30,435,088				34,462,352
Thereof marketable securities			30,211,169				33,969,390
Financial liabilities at amortized cost
Trade and other payables			5,608,204				11,549,150
Financial liabilities at fair value
Current liabilities to shareholders			5,802,128				—

Schedule of Cash and Cash Equivalents

Cash and cash equivalents

		December 31, 2025				December 31, 2024
		(in €)
Short-term deposits
Deposits held in U.S. dollars			7,510,452				13,408,478
Deposits held in Euro			7,235,080				700,000
Total			14,745,532				14,108,478
Cash at banks
Cash held in U.S. dollars			843,915				2,805,655
Cash held in Euro			432,724				1,461,847
Total			1,276,639				4,267,501
Total cash and cash equivalents			16,022,171				18,375,979

Schedule of Trade Payables and Other Accrued Liabilities

Trade payables and other accrued liabilities

		December 31, 2025				December 31, 2024
		(in €)
Accrued liabilities from R&D projects			3,424,362				6,609,925
Accrued liabilities from commercial activities			8,000				69,250
Accounts payable			972,383				3,413,064
Other accrued liabilities and payables			1,353,593				1,603,538
Total			5,758,338				11,695,777

Schedule of Senior Management Oversees The Management of These Risks

The Group’s senior management oversees the management of these risks.

		Exposure		Measurement		Risk Management
Market risk		Future development costs; Recognized financial assets and liabilities not denominated in Euro		Forecasted cash flows Sensitivity analysis		Achievement of a natural hedge in the future
Credit risk		Cash and cash equivalents, current and non-current financial assets		Credit rating		Diversification of bank deposits, Investment guidelines for debt investments
Liquidity		R&D and G&A cost, equity, trade and other payables		Rolling cash flow forecast		Availability of funds through financing rounds or public offerings

Schedule of Cash, Cash Equivalents and Financial Assets

In 2025, if the Euro had weakened/strengthened by 10% against the U.S. dollar with all other variables held constant, the Group’s loss would have been €4.0 million higher/€3.3 million lower, mainly as a result of foreign exchange on translation of U.S. dollar-denominated assets of InflaRx N.V. and InflaRx GmbH.

Cash, cash equivalents and financial assets denominated in U.S. dollars, InflaRx N.V. and InflaRx GmbH		December 31, 2025				December 31, 2024
		(in €)
Current and non current financial assets (securities and accrued interest)			28,434,961				37,316,756
Cash and cash equivalents			8,354,358				14,983,597
Total assets exposed to the risk			36,789,319				52,300,353
Conversion rate Euro to U.S. dollars at reporting date 1/1.1750

Schedule of Sensitivity Analysis

Sensitivity analysis:		Conversion rate				Profit/(loss)				Carrying amount
		(in €)
Euro strengths against U.S. dollars			1.2925				(3,344,484	)			33,444,835
Euro weakens against U.S. dollars			1.0575				4,087,702				40,877,021

Schedule of Outstanding Financial Commitments

At the end of the reporting period, the Group held the following deposits that are expected to readily generate cash inflows to meet the outstanding financial commitments.

Liquidity		December 31, 2025				December 31, 2024
		(in €)
Short-term deposits			14,745,532				14,108,478
Cash at banks			1,276,639				4,267,501
Marketable Securities (current and non-current)			30,214,669				36,829,741
Other (non-current portion)			237,373				237,886
Other (current)			223,932				5,574,734
Total funds available			46,698,145				61,018,339